Investor Relations Corporate Profile Assembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Minimum 15 minutes delayed. Source: LSEG Press Releases See all news Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Events & Presentations See all upcoming events Jul 13 - Jul 17, 2024 48th Annual International Herpesvirus Workshop (IHW) Jun 5 - Jun 8, 2024 EASL 2024 – The International Liver Congress Nov 10 - Nov 14, 2023 AASLD – The Liver Meeting® 2023 Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Investor Relations Corporate Profile Assembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Minimum 15 minutes delayed. Source: LSEG Press Releases See all news Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Events & Presentations See all upcoming events Jul 13 - Jul 17, 2024 48th Annual International Herpesvirus Workshop (IHW) Jun 5 - Jun 8, 2024 EASL 2024 – The International Liver Congress Nov 10 - Nov 14, 2023 AASLD – The Liver Meeting® 2023
